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Michael Domanski, MD,* Valentin Fuster, MD, PHD,* for the FREEDOM InvestigatorsABSTRACTBACKGROUND The prospective, randomized FREEDOM (Comparison of Two Treatments for Multivessel Coronary
Artery Disease in Individuals With Diabetes) trial found coronary artery bypass graft surgery (CABG) was associated with
better clinical outcomes than percutaneous coronary intervention (PCI) in patients with diabetes and multivessel disease,
managed with or without insulin.
OBJECTIVES In this subgroup analysis of the FREEDOM trial, we examined the association of long-term clinical
outcomes after revascularization in patients with insulin-treated diabetes mellitus (ITDM) compared with patients
not treated with insulin.
METHODS A total of 1,850 FREEDOM subjects had an index revascularization procedure performed: 956
underwent PCI with drug-eluting stents (DES), and 894 underwent CABG. A total of 602 patients (32.5%) had
ITDM (PCI/DES n ¼ 325, 34%; CABG n ¼ 277, 31%). Subjects were classiﬁed according to ITDM versus non-ITDM,
with comparison of PCI/DES versus CABG for each group. Interaction analyses were performed for treatment by
diabetes mellitus (DM) status alone and for treatment by DM status by coronary lesion complexity. Analyses were
performed for the primary outcome composite of death/stroke/myocardial infarction (MI) using all available
follow-up data.
RESULTS The overall 5-year event rate of death/stroke/MI was signiﬁcantly higher in ITDM versus non-ITDM patients
(28.7% vs. 19.5%, p < 0.001), which persisted even after adjustment for multiple baseline factors, angiographic
complexity, and revascularization treatment group (death/stroke/MI hazard ratio [HR]: 1.35, 95% conﬁdence interval
[CI]: 1.06 to 1.73, p ¼ 0.014). With respect to the primary composite endpoint, CABG was superior to PCI/DES in both DM
types and the magnitude of treatment effect was similar (interaction p ¼ 0.40) for ITDM (PCI vs. CABG HR: 1.21; 95% CI:
0.87 to 1.69) and non-ITDM patients (PCI vs. CABG HR: 1.46; 95% CI 1.10 to 1.94), even after adjusting for the angio-
graphic SYNTAX score level. Based on 5-year event rates, the number needed to treat with CABG versus PCI to prevent
1 event is 12.7 in ITDM and 13.2 in non-ITDM.
CONCLUSIONS In patients with diabetes and multivessel coronary artery disease, the rate of major adverse cardio-
vascular events (death, MI, or stroke) is higher in patients treated with insulin than in those not treated with insulin.
Furthermore, we did not detect a signiﬁcant difference in the magnitude of PCI versus CABG treatment effect for patients
treated with insulin and those not treated with insulin. (Comparison of Two Treatments for Multivessel Coronary Artery
Disease in Individuals With Diabetes [FREEDOM]; NCT00086450) (J Am Coll Cardiol 2014;64:1189–97) © 2014 by the
American College of Cardiology Foundation.
ABBR EV I A T I ON S
AND ACRONYMS
BMI = body mass index
BUN = blood urea nitrogen
CABG = coronary artery bypass
graft surgery
CI = conﬁdence interval
DES = drug-eluting stent(s)
DM = diabetes mellitus
HR = hazard ratio
ITDM = insulin-treated
diabetes mellitus
ITT = intention-to-treat
MI = myocardial infarction
MVD = multivessel coronary
disease
PCI = percutaneous coronary
intervention
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1190TABLE 1 Baseline and Procedural Characteristics by ITDM Status
Non-ITDM
(n ¼ 1,248)
ITDM
(n ¼ 602) p Value
Age, yrs 63.2  8.9 62.6  9.2 0.16
Male 76.5 61.3 <0.0001
Body mass index, g/m2 29.3  5.0 30.5  5.9 <0.0001
Duration of diabetes, yrs 7.7  7.2 15.1  9.9 <0.0001
Hemoglobin A1c, % 7.5  1.6 8.5  1.8 <0.0001
BUN, mg/dl 21.0 (15.4–32.0) 23.1 (16.1–36.0) 0.02
History of hypertension (83.2) 87.5 0.02
Peripheral neuropathy 5.2 14.3 <0.0001
Current smoker 14.7 17.9 0.07
Previous MI 25.8 25.6 0.92
Previous stroke 3.1 3.8 0.44
Congestive heart failure 24.3 32.1 0.0004T he global prevalence of diabetesmellitus (DM) among adults is cur-rently estimated to exceed 6.4%
(285 million individuals) and is projected
to grow to 7.7% (439 million individuals)
by 2030, making diabetes and its complica-
tions important public health problems (1).
Currently, approximately 26% of the U.S.
patients with diabetes are treated with insu-
lin (ITDM) (2), and these patients are known
to be at higher risk for complications after
coronary reperfusion than both patients
with non-ITDM and patients without dia-
betes (3,4). DM plays an important role inSEE PAGE 1198
NYHA functional class I 75.7 67.9 0.0004
Number of diseased vessels
2 17.7 14.8 0.13
3 82.3 85.2
Total lesion length, mm 77.2  33.8 79.0  33.0 0.26
Any total occlusion in 23.2 23.0 0.92accelerated atherogenesis and atherothrom-
bosis (5), and patients with diabetes areLAD, RCA, or LCx
LV ejection fraction 66.3  11.1 65.7  11.9 0.34
EuroSCORE 2.5  2.4
1.7 (1.2–3.0)
2.9  2.4
2.1 (1.3–3.0)
<0.0001
SYNTAX score 26.0  8.6
26.0 (19.5–31.0)
26.4  8.5
26.0 (20.0–31.0)
0.33
Acute coronary syndrome 28.6 35.1 0.005
Number of PCI lesions 3.5  1.4 3.5  1.4 0.97
Number of CABG grafts 2.9  0.8 3.0  0.8 0.05
Values are mean  SD, %, or median (interquartile range).
BUN ¼ blood urea nitrogen; CABG ¼ coronary artery bypass graft surgery;
ITDM ¼ insulin-treated diabetes mellitus; LAD ¼ left anterior descending coronary
artery; LCx ¼ left circumﬂex coronary artery; LV ¼ left ventricular; MI ¼
myocardial infarction; NYHA ¼ New York Heart Association; PCI ¼ percutaneous
coronary intervention; RCA ¼ right coronary artery.prone to develop multivessel coronary disease
(MVD) (6–8). Despite a high technical success rate
with MVD stenting, those treated with insulin have
a higher rate of coronary artery bypass graft surgery
(CABG) or repeat percutaneous coronary intervention
(PCI), a higher risk of stent thrombosis, and lower 1-
year survival than nondiabetic patients (9,10).
Recently, the FREEDOM (Comparison of Two Treat-
ments for Multivessel Coronary Artery Disease in Indi-
viduals With Diabetes) trial demonstrated that for
patients with diabetes and MVD, CABG is superior to
PCI with drug-eluting stents (DES) in that it signiﬁ-
cantly reduced rates of death and myocardial infarc-
tion (MI), albeit with a higher rate of stroke (11).
Previous CABG reports had shown that ITDM patients
have a particularly elevated risk of in-hospital
morbidity and wound infections after CABG, leading
to a prolonged length of hospital stay, elevated 30-
day mortality, and increased risk of readmission for
cardiac causes (12–14).
The aims of the present study were: 1) to provide
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TABLE 2 Baseline and Procedural Characteristics by ITDM Status and Treatment Arm
Non-ITDM ITDM
PCI
(n ¼ 631)
CABG
(n ¼ 617) p Value
PCI
(n ¼ 325)
CABG
(n ¼ 277) p Value
Age, yrs 63.2  8.8 63.3  9.1 0.85 63.2  9.2 61.9  9.2 0.08
Male 79.1 73.9 0.03 61.9 60.7 0.76
Body mass index, g/m2 29.1  4.9 29.6  5.1 0.04 30.6  6.0 30.3  5.8 0.54
Duration of diabetes, yrs 7.5  7.3 8.0  7.2 0.27 15.1  9.9 15.1  10.0 0.99
Hemoglobin A1c, % 7.5  1.6 7.5  1.6 0.56 8.5  1.8 8.5  1.7 0.89
BUN, mg/dl 21.0 (15.4–32.0) 21.4 (15.3–32.0) 0.79 23.9 (16.7–36.0) 22.2 (16.0–36.0) 0.33
History of hypertension 83.2 83.1 0.98 86.8 88.5 0.53
Peripheral neuropathy 4.3 6.2 0.14 15.4 13.0 0.40
Current smoker 13.2 16.2 0.13 18.2 17.7 0.88
Previous MI 25.8 25.8 0.98 25.5 25.6 0.98
Previous stroke 2.9 3.4 0.58 5.5 1.8 0.02
Congestive heart failure 23.8 24.8 0.67 28.3 36.5 0.03
NYHA functional class I 76.2 75.2 0.67 71.7 63.5 0.03
Diseased vessels
2 18.3 17.0 0.53 16.1 13.4 0.36
3 81.7 83.0 84.0 86.6
Any total occlusion in LAD, RCA, or LCx 21.9 24.5 0.27 24.3 21.4 0.39
LV ejection fraction 65.9  11.9 66.8  10.2 0.23 65.3  12.5 66.1  11.1 0.47
EuroSCORE 2.5  2.2
1.7 (1.2–2.9)
2.6  2.5
1.7 (1.3–3.1)
0.49 3.0  2.6
2.1 (1.3–3.6)
2.8  2.3
2.1 (1.3–3.6)
0.61
SYNTAX score 26.1  8.3
26 (20–31)
25.8  8.9
25 (19–31)
0.50 26.3  8.5
25 (21–31)
26.5  8.5
26.8 (20–32)
0.73
Acute coronary syndrome 30.0 27.2 0.29 34.5 35.7 0.74
No. PCI lesions 3.5  1.4 3.5  1.4
No. CABG grafts 2.9  0.8 3.0  0.8
Values are mean  SD, %, or median (interquartile range).
Abbreviations as in Table 1.
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1191METHODS
The patient population in the FREEDOM trial has
been described in detail previously (11,15). In brief,
the multicenter, open-label prospective randomized
superiority trial evaluated PCI/DES versus CABG in
1,900 diabetic patients in whom revascularization
was indicated with stenosis of more than 70% in 2
or more major epicardial vessels, involving at least
2 separate coronary artery territories, and without
left main coronary stenosis. Consenting diabetic pa-
tients with MVD were randomized on a 1:1 basis
to either CABG or multivessel stenting with DES
and observed up to 7 years (minimum 2 years; median
4 years). Patients randomized to the PCI/DES arm
received any approved DES (sirolimus-eluting and
paclitaxel-eluting were the predominant stents)
per operator’s choice. In this post-hoc analysis, we
classiﬁed subjects into PCI/DES versus CABG based
on the actual treatment received (non–intention-
to-treat [ITT]) and analyzed outcomes occurring
post-procedure: 1,850 FREEDOM subjects with thisdeﬁnition had an index procedure: 956 PCI and 894
CABG procedures were performed.
MEASURES. Patients were categorized as ITDM if
they indicated baseline use of insulin (either alone
or in combination with other oral antidiabetic medi-
cation). To systematically assess angiographic com-
plexity, SYNTAX (Synergy Between PCI With TAXUS
and Cardiac Surgery) score (16), including chronic
total occlusions, were calculated and evaluated based
on angiographic core laboratory interpretations con-
ducted at the Cardiovascular Research Foundation
in New York, New York. Overall, chronic total occlu-
sion and bifurcation statistics were based on total
number of lesions (N ¼ 11,219), and not on number of
subjects. The primary outcome was the composite
(earliest occurring) of all-cause death/MI/stroke using
all available follow-up data.
STATISTICS. Categorical variables are described us-
ing a count and percentage, and continuous variables
by mean and SD, or median and interquartile
range. The distributions of categorical variables by
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Trmt x ITDM interaction P=0.40
CENTRAL ILLUSTRATION Estimates of the Primary Endpoint by Treatment
Received and Insulin Use
(Top) Kaplan-Meier estimated percentage of subjects achieving the primary composite
outcome by insulin use, with point-wise 95% conﬁdence bands (salmon ¼ non-ITDM;
blue ¼ ITDM). (Bottom) Kaplan-Meier estimated percentage of subjects achieving the
primary composite outcome by treatment received and insulin use (interaction p ¼ 0.40).
The median follow-up was somewhat lower in the CABG survivors within the ITDM cohort
(42.7 months) compared with the other 3 groups (median 48.0 months for PCI ITDM; 47.6
months for PCI non-ITDM; 48.0 for CABG non-ITDM). CABG ¼ coronary artery bypass
graft surgery; CI ¼ conﬁdence interval; ITDM ¼ insulin-treated diabetes mellitus;
MI ¼ myocardial infarction; PCI ¼ percutaneous coronary intervention; Trmt ¼ treatment.
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1192treatment group and by ITDM status were compared
using a Fisher exact test. The Wilcoxon rank sum test
was used to compare the distributions of blood urea
nitrogen (BUN), creatinine, euroSCORE, by treatment
arm and by ITDM status, whereas the Student t test
was used for the remaining continuous variables.
Event-free survival rates were estimated using theKaplan-Meier method, and the time to event for
ITDM versus non-ITDM patients was compared using
the log-rank test, using all available follow-up data.
Two- and 5-year point estimates are presented. For
the primary endpoint and secondary endpoints, a
Cox proportional hazards regression test of interac-
tion (treatment received by ITDM status) was used
to assess whether there was a differential treatment
effect by ITDM status using all available follow-up.
Multivariable Cox regression of the primary end-
point was utilized to identify whether ITDM status is
an independent predictor of outcome. Key results
also are presented in the ITT population and con-
tained in the Online Appendix. To construct the
multivariable model, we ﬁrst examined univariate
Cox models, and variables that were at least
marginally associated with the endpoint (p < 0.20)
were included in a model in which stepwise selec-
tion was used for predictor selection at each step.
Additional candidate variables were included into
the multivariable model if there were signiﬁcant
treatment by predictor interactions (p # 0.05).
Finally, we also included measures that were sig-
niﬁcant predictors of ITDM status. Subgroup ana-
lyses were performed for ITDM status and treatment
group, according to the angiographic SYNTAX score.
Our ﬁndings are reported as hazard ratios (HRs) with
95% conﬁdence intervals (CIs). A p value <0.05 was
considered signiﬁcant.
RESULTS
Nearly one-third (32.5%) of subjects had ITDM (602
of 1,850). As summarized in Table 1, ITDM was more
prevalent in females (38.7% vs. 23.5%) and in pa-
tients with a history at baseline of hypertension
(87.5% vs. 83.2%), peripheral neuropathy (14.3% vs.
6.2%), congestive heart failure (32.1% vs. 24.3%),
and acute coronary syndrome (35.1% vs. 28.6%).
ITDM was also signiﬁcantly associated with higher
baseline body mass index (BMI) (30.5  5.9 g/m2 vs.
29.3  5.5 g/m2), longer duration of diabetes (mean 15.1
 9.9 vs. 7.7  7.2 years), and higher hemoglobin A1c
(8.5  1.8% vs. 7.5  1.6%), BUN (median 23.1 vs. 21.0
mg/dl), and EuroSCORE (median 2.1 vs. 1.7). Baseline
medications associated with ITDM were anticoagu-
lants (21% ITDM vs. 12% non-ITDM; primarily heparin,
19% ITDM vs. 11% non-ITDM), antiangina agents
(91% vs. 87%), lipid-lowering agents (89% vs. 84%),
and other cardiac medical therapy (88% vs. 80%; pri-
marily loop diuretics and angiotensin-converting
enzyme inhibitors) (Online Table 1).
In Table 2, we summarized the patient baseline
characteristics within the ITDM versus non-ITDM
TABLE 3 ITDM Versus Non-ITDM Hazard Ratios for FREEDOM Trial Outcomes
Endpoint
ITDM vs. Non-ITDM
Hazard Ratio 95% CI p Value*
Death/stroke/MI 1.63 1.32–2.02 <0.001
All-cause mortality 1.54 1.16–2.05 0.003
Stroke 1.86 1.07–3.02 0.026
MI 1.64 1.18–2.30 0.004
CV death 1.58 1.11–2.26 0.012
30-day MACCE 1.54 1.02–2.33 0.040
1-yr MACCE 1.51 1.18–1.92 0.001
30-day repeat revascularization 1.20 0.64–2.27 0.57
1-yr repeat revascularization 1.44 1.05–1.97 0.025
Hazard ratios are based on all available follow-up for the primary endpoint and its components.
*Cox proportional hazards regression Wald test.
CI ¼ conﬁdence interval; CV ¼ cardiovascular; FREEDOM ¼ Comparison of Two Treatments for
Multivessel Coronary Artery Disease in Individuals With Diabetes; MACCE ¼ major adverse cardiac
and cerebrovascular event(s); other abbreviations as in Table 1.
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1193subgroups for patients treated with PCI/DES versus
CABG. In the ITDM group, PCI subjects were more
likely to have a history of stroke (5.5% vs. 1.8%)
and be in New York Heart Association functional class
I (72% vs. 64%), whereas the CABG group had a higher
rate of congestive heart failure (37% vs. 28%). There
were no baseline medication differences except for
more PCI patients being on loop diuretics compared
with those who underwent CABG (20% vs. 12%)
(Online Table 2).
In the non-ITDM group, we found that CABG
subjects were more likely to be female (26% vs.
21%), have a slightly higher BMI, were more often in
angina class 0 to I (70% vs. 65%), and have a higher
mean glucose level on the day of the procedure
(median 149.4 vs. 140.4 mg/dl) (Table 2). There
were no medication differences at baseline except
for PCI subjects being more likely than CABG sub-
jects to receive clopidogrel (27% vs. 19%) (Online
Table 2).
The Central Illustration displays the higher event
rate for patients with ITDM versus non-ITDM
(28.7% vs. 19.5% for the trial primary outcome at
5 years, p < 0.001) (ITT analysis in the Online
Figure 1). Similarly, time to event was strongly
associated with duration of diabetes (p ¼ 0.007).
The event rates were 24.4% versus 20.7% for pa-
tients with diabetes duration $9 years and <9 years,
respectively. For all trial endpoints except 30-day
repeat revascularization, ITDM patients had a
signiﬁcantly higher event rate, with a consistent
approximately 1.5-fold greater risk than non-ITDM
patients (Table 3).
In multivariable analysis of baseline factors and
treatment group, we found that ITDM status was
an independent predictor of the primary outcome,
with ITDM patients having an approximately 1.5-foldTABLE 4 Kaplan-Meier Event-Free Estimated Event Rates for CABG V
Endpoint (%)
Non-ITDM
PCI CABG
5-yr all-cause death/stroke/MI 23.2 (19.4–27.7) 15.6 (12.5–19.5) 1.
5-yr all-cause mortality 14.5 (11.2–18.6) 9.3 (6.9–12.5) 1.
5-yr stroke 1.7 (0.9–3.2) 4.3 (2.7–6.8) 0
5-yr MI 11.9 (9.1–15.6) 4.8 (7.4–3.1) 2.
5-yr CV death 9.3 (6.7–12.9) 5.5 (8.1–3.7) 1.
30-day MACCE 4.1 (2.8–6.0) 4.4 (3.0–6.3) 0.
1-yr MACCE 14.7 (12.1–17.7) 10.3 (8.2–13.0) 1.
30-day repeat revascularization 2.7 (1.7–4.3) 1.5 (0.8–2.8) 1.
1-yr repeat revascularization 10.8 (8.6–13.5) 4.7 (3.2–6.7) 2.
Values are HR (95% CI). The 95% CI and HRs are based on adjudicated events and inte
follow-up for the primary endpoint and its components. *p Value from Cox regression t
HR ¼ hazard ratio; other abbreviations as in Tables 1 and 3.increase in event rate compared with patients
without ITDM (death/stroke/MI HR: 1.35; 95% CI: 1.06
to 1.73; p ¼ 0.014). The model controlled for: Euro-
SCORE, hemoglobin A1c, chronic renal insufﬁciency,
BUN, age, history of stroke, history of MI, low-density
lipoprotein cholesterol, heart rate, left ventricular
ejection fraction, and revascularization treatment
received (CABG vs. PCI/DES).
The treatment effect of CABG versus PCI in the
2 subsets of DM types is shown in Table 4 and the
Central Illustration (ITT analysis in Online Figure 2).
With respect to the primary composite endpoint,
there was no signiﬁcant interaction of treatment
and DM type (p ¼ 0.40) (Table 4, Central Illustration);
there is insufﬁcient evidence to declare a differen-
tial treatment effect in ITDM (PCI vs. CABG HR:
1.21; 95% CI: 0.87 to 1.69; p ¼ 0.009) and non-ITDM
patients (PCI vs. CABG HR: 1.46; 95% CI: 1.10 toersus PCI
ITDM Treatment  Insulin
Interaction
p Value*PCI vs. CABG PCI CABG PCI vs. CABG
46 (1.10–1.94) 32.2 (26.3–39.0) 24.3 (19.1–30.5) 1.21 (0.87–1.69) 0.40
36 (0.94–1.96) 19.0 (14.2–25.0) 14.1 (10.1–19.5) 1.19 (0.76–1.85) 0.64
.51 (0.25–1.06) 3.7 (2.0–6.9) 7.5 (4.5–12.5) 0.60 (0.28–1.30) 0.77
32 (1.45–3.70) 17.7 (12.8–24.3) 8.6 (5.6–23.0) 1.68 (0.99–2.83) 0.37
34 (0.84–2.13) 12.9 (8.9–18.6) 8.9 (5.8–13.5) 1.22 (0.70–2.12) 0.78
94 (0.55–1.61) 6.2 (4.0–9.4) 6.9 (4.4–10.6) 0.89 (0.48–1.67) 0.90
43 (1.04–1.98) 20.7 (16.6–25.5) 15.4 (11.6–20.3) 1.35 (0.92–1.98) 0.81
86 (0.83–4.17) 4.3 (2.6–7.2) 0.4 (0.1–2.7) 12.10 (1.59–92.0) 0.09
38 (1.53–3.70) 16.1 (12.5–20.6) 4.9 (2.9–8.4) 3.47 (1.89–6.39) 0.33
raction p value for treatment by insulin dependency status. HR estimates are based on all available
est of treatment  subgroup interaction using all available follow-up data (i.e., >5 years).
TABLE 5 5-Year Kaplan-Meier Estimated Event Rates for the Primary Endpoint (Death/Stroke/MI)
Group*
Non-ITDM ITDM Treatment  Insulin
Interaction
p ValuePCI CABG PCI vs. CABG PCI CABG PCI vs. CABG
SYNTAX #22
(208, 231, 123, 93)
19.7 (13.0–24.4) 14.1 (9.5–20.75) 1.18 (0.71–1.96) 29.7 (20.2–42.3) 26.3 (17.7–38.0) 0.84 (0.47–1.48) 0.39
SYNTAX 23–32
(305, 255, 138, 129)
23.1 (17.8–29.7) 14.3 (10.1–20.0) 1.61 (1.04–2.49) 35.5 (26.8–46.0) 21.8 (15.2–30.7) 1.56 (0.95–2.57) 0.93
SYNTAX $33
(114, 125, 64, 54)
30.4 (20.9–42.8) 20.0 (12.8–30.4) 1.58 (0.88–2.81) 28.9 (19.3–42.0) 25.9 (15.3–41.9) 1.27 (0.61–2.64) 0.65
Values are HR (95% CI). The 95% CI and HR are based on adjudicated events for the primary endpoint (death/stroke/MI) using all available follow-up and interaction p value for treatment
by insulin dependency status, at each level of angiographic complexity. p Values were derived from Cox regression test of treatment  subgroup interaction using all available follow-up data
(i.e., >5 years). *Numbers in parentheses indicate PCI n, CABG n for each stratum.
Abbreviations as in Tables 1 and 3.
TABLE 6 5-Year Kap
the Primary Endpoint
Group*
SYNTAX #22
(n ¼ 216, 439)
28
SYNTAX 23–32
(n ¼ 267,560)
29
SYNTAX $33
(n ¼ 118,239)
27
The 95% CI and HR are
available follow-up and int
parentheses indicate ITDM
Abbreviations as in Tabl
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11941.94; p ¼ 0.33). The results for the ITT population
are provided in the Online Figures 1 and 2, and are
qualitatively identical to the non-ITT results,
showing no signiﬁcant interaction of treatment and
DM type (p ¼ 0.33) (PCI vs. CABG in ITDM [ITT]
HR: 1.17; 95% CI: 0.85 to 1.63; p ¼ 0.33 and PCI vs.
CABG in non-ITDM [ITT] HR: 1.45; 95% CI: 1.10 to
1.92; p ¼ 0.009).
To detect the observed PCI versus CABG HR of 1.2
with 85% power in the ITDM group at the 0.05 level
would have required approximately 1,200 patients
(i.e., double the size of the ITDM cohort in the
FREEDOM trial).
We found a signiﬁcant CABG beneﬁt over PCI in
non-ITDM patients, whereas because of insufﬁcient
power, our results do not provide sufﬁcient evi-
dence to state a CABG beneﬁt in the ITDM sub-
group. However, the hazard point estimates are in
the same direction for both subgroups, as sup-
ported by the nonsigniﬁcant interaction test,
demonstrating that ITDM/non-ITDM subgroup is
not an effect modiﬁer with regard to the beneﬁtlan Meier Estimated Event Rates With 95% CI and HR for
(Death/Stroke/MI) for ITDM Status by SYNTAX Score
ITDM
5-Yr Rate
Non-ITDM
5-Yr Rate
ITDM vs.
Non-ITDM
ITDM  SYNTAX
Interaction
p Value
.5% (21.5–37.1) 16.4% (12.6–21.3) 1.90 (1.30–2.78)
.4% (23.5–36.4) 19.1% (15.5–23.4) 1.61 (1.17–2.22) 0.59
.7% (20.1–35.5) 24.8% (32.6–18.7) 1.40 (0.88–2.21)
based on adjudicated events for the primary endpoint (death/stroke/MI) using all
eraction p value (Cox regression) for ITDM status by SYNTAX score. *The numbers in
n, non-ITDM n for each stratum.
es 1, 3, and 4.of CABG over PCI in patients with diabetes and
MVD.
If the subgroup is disregarded, the HR was 1.38
(95% CI: 1.11 to 1.71; p ¼ 0.004). Similarly, there was
no interaction of treatment by duration of diabetes
(p ¼ 0.12 for continuous duration and p ¼ 0.41
for duration <9 years vs. $9 years). Consistent with
these ﬁndings, based on 5-year event rates, the
number needed to treat with CABG versus PCI to
prevent 1 event was similar for the 2 subgroups:
12.7 in ITDM and 13.2 in non-ITDM.
Treatment by DM group interactions were also
analyzed within SYNTAX score–level (angiographic
complexity), without ﬁnding any difference in the
comparison of PCI/DES versus CABG effect size
dependency on DM group (Table 5) with respect to
the 5-year Kaplan-Meier estimated event rates and
HRs based on adjudicated events for the primary
endpoint of death/MI/stroke. Table 6 shows that
there was no signiﬁcant interaction with respect to
the same 5-year outcome between the ITDM status
and SYNTAX score.
We also explored whether the relative hazard of
death/stroke/MI for PCI versus CABG patients was
different in the ﬁrst 2 years post-procedure compared
with after 2 years, both in the overall cohort and
within the ITDM and non-ITDM groups. There was
evidence of nonproportional hazards (p < 0.001),
with no signiﬁcant PCI versus CABG effect before
2 years (HR: 1.11 overall, 1.06 for ITDM, 1.12 for non-
ITDM), but an increased hazard for PCI patients
after 2 years (HR: 2.06 overall, 1.52 for ITDM, 2.46
for non-ITDM) (Table 7).
DISCUSSION
In this secondary analysis of the FREEDOM trial,
we examined the association of ITDM status and
TABLE 7 PCI Versus CABG Hazard Ratios for FREEDOM Primary Outcome of
All-Cause Death/Stroke/MI: Time-Dependent Cox Regression Modeling
Results*
Group
<2 Yrs Post-Procedure $2 Yrs Post-Procedure
Hazard Ratio
(95% CI)
p
Value
Hazard Ratio
(95% CI)
p
Value
All (n ¼ 1,850) 1.11 (0.85–1.45) 0.44 2.06 (1.41–3.02) <0.001
ITDM (n ¼ 602) 1.06 (0.70–1,61) 0.78 1.52 (0.86–2.70) 0.15
Non-ITDM (n ¼ 1,248) 1.12 (0.79–1.58) 0.54 2.46 (1.48–4.09) <0.001
*Treatment group  time period interaction p values ¼ 0.009 for all, 0.32 for ITDM, 0.012
for non-ITDM.
Abbreviations as in Tables 1 and 3.
J A C C V O L . 6 4 , N O . 1 2 , 2 0 1 4 Dangas et al.
S E P T E M B E R 2 3 , 2 0 1 4 : 1 1 8 9 – 9 7 The FREEDOM Insulin Subgroup Analysis
1195clinical outcomes after revascularization with CABG
or PCI/DES. Our main ﬁndings were: 1) clinical event
rates were higher in patients with ITDM than in those
not treated with insulin; and 2) there was no signiﬁ-
cant interaction of treatment and DM type, indicating
that there is insufﬁcient evidence to declare a dif-
ferential treatment effect in ITDM and non-ITDM
patients (Central Illustration). Although a nonsigniﬁ-
cant interaction test does not deﬁnitively demon-
strate that treatment effects within subgroups are
similar, we do not feel that the HRs were highly
clinically different. This also was maintained after
angiographic stratiﬁcation for lesion complexity.
Indeed, the SYNTAX score derived from the base-
line angiogram was similar in the 2 DM subgroups,
which also is supported by the target lesion length
being similar in the 2 ITDM and non-ITDM patient
groups.
In addition, we observed that ITDM patients were
more often female, had higher BMI, hemoglobin
A1c, and BUN levels than non-ITDM patients, and
were more likely to have a history of stroke, hyper-
tension, congestive heart failure, and acute coronary
syndrome when compared with non-ITDM patients. A
higher primary outcome event rate was associated
with a longer duration of diabetes. However, similar
to our primary ﬁnding using ITDM status, there was
no signiﬁcant interaction of revascularization mode
and duration of insulin treatment.
There were very few differences in baseline
characteristics between CABG and PCI/DES treat-
ment within either the ITDM or the non-ITDM
strata, and these differences were not variables
that are known to be strong risk factors for adverse
outcome. Earlier reports based on data from the
CARDia (Coronary Artery Revascularization in Dia-
betes) trial (17) and the 5-year results of the SYNTAX
trial (16) indicated signiﬁcantly higher rates of major
adverse cardiac and cerebrovascular events in pa-
tients with diabetes treated with PCI compared
with those treated with CABG (18). The present
analysis extends these ﬁndings by showing that
regardless of ITDM status and SYNTAX score,
CABG treatment is superior to PCI/DES, not only in
repeat revascularization, but also in a signiﬁcant
reduction in all-cause death and MI in patients with
diabetes and MVD.
Our results lend support to a recent meta-analysis
of several randomized trials of CABG versus PCI,
which found lower mortality rates in diabetic pa-
tients revascularized with CABG compared with PCI
(19), as well as to prospective registry data of
consecutive CABG patients that reported mortality
to be signiﬁcantly higher in patients with ITDM,compared with non-ITDM or non-diabetic patients
(3). The increased stroke rate following CABG
compared with PCI is also independent of ITDM
status (5-year rates of 7.5% vs. 3.7% for CABG and
PCI ITDM patients; and 4.3% vs. 1.7% for CABG and
PCI non-ITDM patients). This is consistent with a
prior meta-analysis reporting on post-CABG versus
post-PCI stroke rates (post-CABG stroke rate at 1
year of 1.83%; odds ratio of 1.67 compared with
PCI) (20).
We documented that insulin-treated patients have
worse clinical outcome regardless of the treatment
arm, which may either be due to more aggressive
disease in these patients or an adverse effect of
insulin.
Iatrogenic hyperinsulinemia controls hyperglyce-
mia in ITDM but also may promote proinﬂammatory
macrophage responses and stimulate hormonal
overactivation of signal transduction pathways,
which affects progression of atherogenesis and dis-
turbs hemodynamic control and cardiovascular
function by disrupting the balanced synthesis
and release of endothelial mediators (21–23). The
associated clinical manifestations described include
essential hypertension (24), pathological cardiac hy-
pertrophy with chronic pressure overload (25), as
well as myocardial hypoxia (26), heart failure (27–29),
and weight gain, in turn promoting proinﬂammatory
effects (30). At the same time, insulin might be a
marker of high-risk patients, not only because of
more severe insulin resistance but also because of
more prolonged DM (5,30,31).
STUDY LIMITATIONS. The present study was limited
by the small stratum sizes for the analyses of outcome
by DM status by SYNTAX score; hence, the conﬁdence
intervals for the stratum-speciﬁc event rates were
rather wide. The precise determination of the PCI
versus CABG treatment difference in ITDM patients
with extensive coronary artery disease can be more
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: In the
FREEDOM trial, CABGwas associatedwith better clinical
outcomes than PCI in patients with diabetes and multi-
vessel disease managedwith or without insulin. Patients
on insulin had higher event rates compared to those
not on insulin regardless of revascularization mode.
COMPETENCY IN PATIENT CARE: Consultation
with a cardiac surgeon should be obtained before
multivessel myocardial revascularization in a patient
with diabeteswho has angina pectoris or its equivalent.
TRANSLATIONAL OUTLOOK: Adequately pow-
ered randomized trials are needed to conﬁrm the
superiority of CABG in patients with insulin-dependent
diabetes mellitus who have multivessel coronary
disease, left main coronary artery disease, or undergo
PCI with later-generation drug-eluting stents.
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1196accurately determined in a dedicated, prospective
study. In addition, few baseline characteristics
differed between ITDM PCI and ITDM CABG
subgroups.
CONCLUSIONS
In patients with diabetes and multivessel coronary
artery disease, the rate of major adverse cardio-
vascular events (death, MI, or stroke) is higher in
patients treated with insulin than in those not
treated with insulin. Furthermore, we did not
detect a signiﬁcant difference in the magnitude of
PCI versus CABG treatment effect for patients
treated with insulin and those not treated with
insulin.
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this article.
